ProMIS Slides To FY25 Net Loss; Expects Interim Data From Phase 1b Trial Of PMN310 In Early Q3 2026

ProMIS Neurosciences reported full-year 2025 financial results and provided updates on its lead investigational Alzheimer's candidate PMN310; the article does not disclose specific revenue, EPS, or cash-runway figures. The company remains clinical-stage and the PMN310 update is the key operational development; detailed clinical data or milestone timelines will be required to assess material impact on valuation and near-term stock performance.

Analysis

ProMIS Neurosciences reported full-year 2025 financial results and provided updates on its lead investigational Alzheimer's candidate PMN310; the article does not disclose specific revenue, EPS, or cash-runway figures. The company remains clinical-stage and the PMN310 update is the key operational development; detailed clinical data or milestone timelines will be required to assess material impact on valuation and near-term stock performance.